您的当前位置：首页 > 영화 > Daewoong aims to reshape obesity market with patch 正文
时间：2023-12-04 03:45:12 来源：网络整理 编辑：영화
Daewoong Pharmaceutical said Monday the company will develop a microneedle-based obesity treatment d
Daewoong Pharmaceutical said Monday the company will develop a microneedle-based obesity treatment drug.
The South Korean pharmaceutical company aims to start a phase 1 clinical trial next year and launch the treatment in 2028.
Daewoong Pharmaceutical’s new obesity treatment will contain a synthetic peptide semaglutide, which is similar to glucagon-like peptide-1 (GLP-1), a hormone produced in the gut released in response to food to reduce appetite and the release of insulin.
The patch-type obesity treatment, measuring 1 square centimeter, will use drug-loaded dissolvable microneedles to penetrate the outer layer of the skin to deliver drug ingredients to the patient’s body. The company said patients will be able to easily administer the treatment and minimize injections-associated fears involving existing injection-type GLP-1 agonists.
“The patch-type obesity treatment will increase overall medication adherence of patients with obesity who have to take the treatment on a regular basis,” an official from Daewoong Pharmaceutical said. Daewoong Pharmaceutical said patients will need to use its patch-type obesity treatment just once a week.
Daewoong Pharmaceutical added the new treatment also aims to eliminate common side effects like skin swelling or lumps to improve the treatment experience.
For the development of the patch-type obesity treatment, Daewoong Pharmaceutical will also apply its own microneedle platform technology known as closed-packed aero-pressured microneedle (CLOPAM).
“While microneedles have been widely used in cosmetics, their application in medicine has been limited due to issues involving drug capacity and transdermal absorption. Daewoong Pharmaceutical’s CLOPAM technology is designed to ensure efficient drug delivery and minimize drug loss,” the official said.
Daewoong Pharmaceutical's microneedle platform technology will allow patients to store and use the treatment at room temperature, the official added.
Daewoong Pharmaceutical's microneedle platform has been developed by its research and development unit Daewoong Therapeutics. Daewoong Pharmaceutical has filed 23 patents in South Korea and registered six international patents for the microneedle technology. The company said it has received a proposal from a global pharmaceutical firm to develop other microneedle-based medications.
With the development of patch-type obesity treatment, Daewoong aims to enter the rapidly growing global obesity treatment market, it said. The global market for obesity treatments is expected to grow to 104 trillion won ($80 billion) by 2030, the firm said, quoting data from Morgan Stanley.
"Daewoong Pharmaceutical will push ahead with the development of the new patch-type obesity treatment for patients with unmet medical needs," Daewoong Pharmaceutical CEO Jeon Seung-ho said.
Meanwhile, Daewoong Pharmaceutical is also conducting studies to develop its new diabetes drug Enblo as a potential treatment for obesity.
Big firms' debt2023-12-04 03:01
'Do not open plane doors' warning mandated for planes in flight2023-12-04 02:15
Seoul shares end lower amid conflict in Middle East2023-12-04 02:10
Half of Loona restarts as quintet Loossemble2023-12-04 01:37
Hillstate Gayang flats in Daejeon to go on sale2023-12-04 01:23
Performing Arts Market to link local artists to world2023-12-04 01:09
Korea to showcase advanced climate technologies at COP28 Dubai2023-12-04 03:14
Seoul shares close tad higher ahead of key US jobs data2023-12-04 02:44
Four days of jazz festivities take over Jara Island2023-12-04 02:30
New NZ minister takes oath in English and Korean2023-12-04 02:14
Shinhan to bet big on insurance tech startup2023-12-04 01:51
Kakao Bank to acquire 10% stake in Indonesian digital bank2023-12-04 01:48
김건희 여사, 광주디자인비엔날레 찾아 “문화예술계 육성 의지”2023-12-04 01:44
Hyundai Elevator, Erbud team up to rebuild Ukraine2023-12-04 01:39